• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

支架厚度对小血管和分叉病变临床结局的影响:RAIN-CARDIOGROUP VII 亚组研究。

Impact of stent thickness on clinical outcomes in small vessel and bifurcation lesions: a RAIN-CARDIOGROUP VII sub-study.

机构信息

Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza, Hospital, University of Turin, Turin, Italy.

Interventional Cardiology Department, Clinico San Carlos University Hospital, IdISSC, Madrid, Spain.

出版信息

J Cardiovasc Med (Hagerstown). 2021 Jan;22(1):20-25. doi: 10.2459/JCM.0000000000001037.

DOI:10.2459/JCM.0000000000001037
PMID:32740419
Abstract

BACKGROUND

The clinical impact of stent strut thickness in coronary bifurcation lesions in small vessels has not been assessed in a real-world population.

METHODS

All 506 patients enrolled in the RAIN study, undergoing PCI in a vessel with a diameter 2.5 mm or less were retrospectively evaluated and divided into two groups according to stent strut thickness: 74 μm (n = 206) versus 81 μm (n = 300); 87.1% of the lesions involved bifurcations. TLF [defined as a composite of myocardial infarction (MI) and target lesion revascularization (TLR)] was the primary endpoint, with MACE (a composite of death, MI and TLR), its components and stent thrombosis the secondary endpoint.

RESULTS

After 16 (14-18) months, a lower incidence of TLF (4.3 vs. 9.8%, P = 0.026) and ST (1.0 vs. 3.0%, P = 0.042) was seen in the 74 μm group, whereas MACE occurred in 60 of 506 patients, with no statistical difference between the two groups (9.7 vs. 13.3%, P = 0.070). At multivariate analysis, chronic renal failure increased the risk of TLF while thinner strut was an independent protective factor (hazard ratio 0.51, CI 0.17-0.85, P = 0.005).

CONCLUSION

In this real-world population, patients being treated for small vessels lesions with thinner strut stents had lower rates of TLF, MI and ST.

摘要

背景

在小血管分叉病变中,支架梁厚度对临床的影响尚未在真实世界人群中得到评估。

方法

回顾性分析了 RAIN 研究中所有 506 例接受直径 2.5mm 或以下血管 PCI 治疗的患者,并根据支架梁厚度将其分为两组:74μm(n=206)和 81μm(n=300);77.6%的病变涉及分叉。TLF(定义为心肌梗死[MI]和靶病变血运重建[TLR]的复合终点)为主要终点,MACE(死亡、MI 和 TLR 的复合终点)、其组成部分和支架血栓形成则为次要终点。

结果

16 个月(14-18 个月)后,74μm 组的 TLF(4.3%比 9.8%,P=0.026)和 ST(1.0%比 3.0%,P=0.042)发生率较低,而 506 例患者中有 60 例发生 MACE,两组之间无统计学差异(9.7%比 13.3%,P=0.070)。多变量分析显示,慢性肾功能衰竭增加了 TLF 的风险,而支架梁较薄则是独立的保护因素(风险比 0.51,95%CI 0.17-0.85,P=0.005)。

结论

在这一真实世界人群中,使用较薄支架梁的患者治疗小血管病变的 TLF、MI 和 ST 发生率较低。

相似文献

1
Impact of stent thickness on clinical outcomes in small vessel and bifurcation lesions: a RAIN-CARDIOGROUP VII sub-study.支架厚度对小血管和分叉病变临床结局的影响:RAIN-CARDIOGROUP VII 亚组研究。
J Cardiovasc Med (Hagerstown). 2021 Jan;22(1):20-25. doi: 10.2459/JCM.0000000000001037.
2
Impact of the metal-to-artery ratio on clinical outcomes in left main and nonleft main bifurcation: insights the RAIN-CARDIOGROUP VII study (veRy thin stents for patients with left mAIn or bifurcatioN in real life).金属对动脉比在左主干和非左主干分叉病变患者临床结局中的影响:RAIN-CARDIOGROUP VII 研究的见解(真实生活中左主干或分叉病变患者使用 veRy 薄支架)。
J Cardiovasc Med (Hagerstown). 2020 Sep;21(9):669-674. doi: 10.2459/JCM.0000000000001010.
3
Comparison of bioresorbable vs durable polymer drug-eluting stents in unprotected left main (from the RAIN-CARDIOGROUP VII Study).无保护左主干时生物可吸收 vs 持久聚合物药物洗脱支架比较(来自 RAIN-CARDIOGROUP VII 研究)。
BMC Cardiovasc Disord. 2020 May 15;20(1):225. doi: 10.1186/s12872-020-01420-5.
4
5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).SPIRIT III 试验的 5 年随机对照研究结果:依维莫司洗脱 XIENCE V 支架与紫杉醇洗脱 Taxus 支架的比较——治疗初发的 native 冠状动脉病变患者的 XIENCE V 依维莫司洗脱冠状动脉支架系统的临床评估。
JACC Cardiovasc Interv. 2013 Dec;6(12):1263-6. doi: 10.1016/j.jcin.2013.07.009. Epub 2013 Nov 13.
5
Impact of structural features of very thin stents implanted in unprotected left main or coronary bifurcations on clinical outcomes.非常薄的支架在未保护的左主干或冠状动脉分叉处植入的结构特征对临床结果的影响。
Catheter Cardiovasc Interv. 2020 Jul;96(1):1-9. doi: 10.1002/ccd.28667. Epub 2019 Dec 20.
6
Safety and efficacy of polymer-free biolimus-eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries.聚合物涂层雷帕霉素洗脱支架与超薄支架治疗无保护左主干或冠状动脉分叉病变的安全性和疗效:RAIN 和 CHANCE 注册研究的倾向评分分析。
Catheter Cardiovasc Interv. 2020 Feb 15;95(3):522-529. doi: 10.1002/ccd.28413. Epub 2019 Aug 5.
7
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).在冠状动脉疾病中,依维莫司洗脱支架与紫杉醇洗脱支架的荟萃分析:SPIRIT 临床试验计划的最终 3 年结果(在治疗新发病变的患者中,使用依维莫司洗脱冠状动脉支架系统治疗的西里斯 V 依维莫司洗脱冠状动脉支架系统的临床评估)。
JACC Cardiovasc Interv. 2013 Sep;6(9):914-22. doi: 10.1016/j.jcin.2013.05.005.
8
Two years clinical outcomes with the state-of-the-art PCI for the treatment of bifurcation lesions: A sub-analysis of the SYNTAX II study.治疗分叉病变的最新 PCI 技术的两年临床结果:SYNTAX II 研究的子分析。
Catheter Cardiovasc Interv. 2020 Jul;96(1):10-17. doi: 10.1002/ccd.28422. Epub 2019 Aug 12.
9
One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in diabetic patients: Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry).ULISSE 注册研究(意大利 ULtimaster 多中心所有入组患者支架注册研究):糖尿病患者中生物可降解聚合物西罗莫司洗脱支架一年临床预后结果。
Catheter Cardiovasc Interv. 2020 Aug;96(2):255-265. doi: 10.1002/ccd.28694. Epub 2020 Jan 6.
10
Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results.经皮冠状动脉分叉病变挤压与 Culotte 支架置入术的临床结果:北欧支架技术研究 36 个月随访结果。
JACC Cardiovasc Interv. 2013 Nov;6(11):1160-5. doi: 10.1016/j.jcin.2013.06.009.

引用本文的文献

1
Evaluating Polylactic Acid and Basalt Fibre Composites as a Potential Bioabsorbable Stent Material.评估聚乳酸与玄武岩纤维复合材料作为潜在的生物可吸收支架材料
Polymers (Basel). 2025 Jul 16;17(14):1948. doi: 10.3390/polym17141948.
2
Outcome of percutaneous coronary intervention using ultrathin-strut biodegradable polymer sirolimus-eluting versus thin-strut durable polymer zotarolimus-eluting stents in patients with comorbid peripheral arterial disease: a post-hoc analysis from two randomized trials.合并外周动脉疾病患者使用超薄支撑可生物降解聚合物西罗莫司洗脱支架与薄支撑耐用聚合物佐他莫司洗脱支架进行经皮冠状动脉介入治疗的结果:两项随机试验的事后分析
Cardiovasc Diagn Ther. 2023 Aug 31;13(4):673-685. doi: 10.21037/cdt-22-584. Epub 2023 Jul 24.
3
Comparison of 7-Year, Real-World Clinical Outcomes between Drug-Coated Balloon Angioplasty versus Drug-Eluting Stent Implantation in Patients with Drug-Eluting Stent In-Stent Restenosis.药物洗脱支架内再狭窄患者中药物涂层球囊血管成形术与药物洗脱支架植入术7年真实世界临床结局的比较
J Clin Med. 2023 Jun 24;12(13):4246. doi: 10.3390/jcm12134246.
4
Complex Coronary Interventions: Are We Reaching a Plateau?复杂冠状动脉介入治疗:我们是否已达到平台期?
J Pers Med. 2022 Aug 8;12(8):1298. doi: 10.3390/jpm12081298.
5
COBRA PzF™ coronary stent in clinical and preclinical studies: setting the stage for new antithrombotic strategies?COBRA PzF™ 冠状动脉支架的临床和临床前研究:为新的抗血栓策略奠定基础?
Future Cardiol. 2022 Mar;18(3):207-217. doi: 10.2217/fca-2021-0057. Epub 2021 Sep 15.